Evaluation of Bupropion Efficacy on Sexual Dysfunction among Male Patients on Methadone Maintenance Therapy
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
Decreased libido and sexual dysfunction (e.g., erectile dysfunction) seem to be the most common adverse effects of long-term methadone usage. To investigate the efficacy of bupropion on sexual dysfunction in men receiving methadone maintenance therapy (MMT), a double-blind, placebo-controlled trial was conducted in the addiction quitting center of Noor and St. Aliasghar Hospital of Isfahan. Sixty male patients receiving MMT for at least six months and having complaints of sexual dysfunction were randomized to treatment (n = 30) with bupropion (200 mg/day) or placebo (n = 30) for eight weeks. Sexual function and depression scores were assessed by Arizona sexual experience scale, and Beck depression inventory II self-reported questionnaires, respectively. The results showed that bupropion could improve sexual dysfunction (P = 0.006), but it showed no effect on depression severity scale (P > 0.05). Our findings suggest that adding bupropion to the current protocols of MMT could be useful in decreasing sexual dysfunction, thus it may result in more adherence to treatment and better outcome. Further studies with control group and greater sample size are warranted to evaluate the efficacy of bupropion on improvement of each phases of sexual function among MMT patients. RCT has been registered in http://irct.ir, code: IRCT2014032616823N1.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- Male
入选标准
- •Male gender;Having the minimum level of education in reading and writing; passing at least 6 months from the Methadone maintenance Therapy( MMT); Having complaints from the cause or aggravate of sexual dysfunction after methadone treatment; Lack of underlying diseases as epilepsy, diabetes, organic brain disease, and psychosis;Not receiving drugs affecting sexual function, such as SSRI, sildenafil, testosterone, antipsychotics, cyclic antidepressants, MAO-I, the lithium, amphetamines, chlordiazepoxide, clonidine, methyldopa, spironolactone hydrochlorothiazide, barbiturates, anti-Parkinson's drugs , clofibrate, digoxin, indomethacin, propranolol and phentolamine; No risk of major depressive disorder and a score of less than 16 based on the BDI-II, Having a total score of 19 or more based on the Arizona Sexual Experience Scale (ASEX) or a score of 5 or more on one of the items of ASEX or a score of 4 or more in any of 3 items; No alcohol consumption, recent cessation of benzodiazepines, and not using drugs or stimulants.
- •Exclusion criteria: Leaving the MMT program; the decision of the therapist to stop the treatment with methadone or bupropion for any reason, and seizures.
排除标准
- 未提供